Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
27,795,576
-
Number of holders
-
63
-
Total 13F shares, excl. options
-
24,490,500
-
Shares change
-
-1,010,840
-
Total reported value, excl. options
-
$17,143,967
-
Value change
-
-$720,822
-
Put/Call ratio
-
376%
-
Number of buys
-
19
-
Number of sells
-
26
-
Price
-
$0.7000
Institutional Holders of Accelerate Diagnostics, Inc. - Common Stock, par value $0.001 per share (AXDX) as of Q1 2023
As of 31 Mar 2023 Accelerate Diagnostics, Inc. - Common Stock, par value $0.001 per share (AXDX) had 63 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 24,490,500 shares of stock of the company.
Largest 10 holders included GRIFFIN ASSET MANAGEMENT, INC., VANGUARD GROUP INC, Birchview Capital, LP, ORACLE INVESTMENT MANAGEMENT INC, Alyeska Investment Group, L.P., Cannell & Co., BlackRock Inc., MILLENNIUM MANAGEMENT LLC, GEODE CAPITAL MANAGEMENT, LLC, and Cladis Investment Advisory, LLC.
This table shows 63 institutional shareholders of the security as of 31 Mar 2023.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.